Skip to main content
  • Poster presentation
  • Published:

Neutralizing IL-17 during re-activation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and IL-1


Rheumatoid arthritis is characterized by an intermittent course of the disease with alternate periods of remission and relapse. T cells, and in particular the T-cell cytokine IL-17, are expected to be involved in this flare-up of arthritis.


To study the role of T-cell IL-17 in flare-up of experimental arthritis.


Antigen-induced arthritis was induced in C57Bl/6 mice by immunizing and boosting with mBSA/ complete Freund's adjuvant, and subsequent intra-articular injection of 60 μg mBSA. At week 4 of arthritis, 2 μg mBSA was injected into the arthritic joint to induce a flare-up of the smouldering inflammation. To study the role of IL-17 in this flare-up, neutralizing rabbit-anti-mouse-IL-17 antibodies (or control antibodies) were injected 2 hours prior to antigen rechallenge.


Quantitative PCR at various time points after arthritis induction showed that IL-17 mRNA expression was already upregulated at day 1, increased even more at day 2 and day 7, and clearly diminished at day 21. After antigen rechallenge, IL-17 mRNA expression rapidly increased, peaking at 4 hours with a 250-fold upregulation compared with naive mice.

Neutralizing IL-17 significantly prevented joint swelling, as measured by 99mTc uptake at day 1 (Fig. 1a). Arthritic knee joints were isolated at day 4, and histological analysis showed significantly suppressed joint inflammation (Fig. 1b) and cartilage proteoglycan depletion in the anti-IL-17-treated group.

Figure 1
figure 1

Joint swelling, (b) inflammation, and (c) bone erosion in arthritic mice before (background) and after flare-up of experimental arthritis, treated with anti-IL-17 antibodies or control antibodies. * P < 0.01, ** P < 0.005 versus control-treated group. R/L ratio, ratio between the mouse right inflamed knee joint (R) and left uninflamed knee joint (L).

Blocking IL-17 also clearly protected arthritic mice against bone erosions (Fig. 1c). Cathepsin K staining showed reduced osteoclast-like activity, and quantitative PCR showed reduced RANKL mRNA expression in the anti-IL-17-treated group. The degree of bone erosions strongly correlated with the severity of joint inflammation, suggesting that neutralizing IL-17 reduces bone erosion by suppressing joint inflammation.

Interestingly, mice treated with anti-IL-17 antibodies showed reduced protein levels of IL-1β, tumor necrosis factor alpha, and the cytokine-induced neutrophil chemoattractant KC, suggesting that IL-17 acts as an upstream mediator in destructive joint inflammation during flare-up of experimental arthritis.


These data indicate IL-17 to be an important upstream proinflammatory cytokine driving joint pathology during flare-up of experimental arthritis and suggest therapeutic benefit of neutralizing IL-17 during relapses of rheumatoid arthritis.

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Koenders, M., Lubberts, E., Joosten, L. et al. Neutralizing IL-17 during re-activation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and IL-1. Arthritis Res Ther 7 (Suppl 1), P53 (2005).

Download citation

  • Received:

  • Published:

  • DOI: